A paper titled published in the @PNASNews from the laboratories of @CWRUSOM professors Andrew Pieper and Sanford Markowitz was awarded the 2025 PNAS Cozzarelli Prize in Biomedical Sciences. Learn more:

Case Western Reserve University has been named one of the world’s top universities, ranking 25th globally in @TIME's inaugural World’s Best Universities list!

My @NIH study section will not meet tomorrow because of the government shutdown. This may seem trivial but rescheduling these meetings will delay funding decisions for months to even a year! Let alone the uncertainty of what the FY26 budget will be. Awful for US scientists! 😓

Excited to share our lab’s new review in @StemCellsJournl! Led by @science_klein with Ritisha Rashmil and Angella Blake, we cover how niche modeling, small molecules, and gene-editing advances are helping generate functional HSCs for therapy.

Excited to be in beautiful San Juan for the Department of Energy @ENERGY “1-2-3 to Cesium Free” workshop. Great talks on alternatives to cesium radiation sources in biomedical research- very relevant to our work @caseccc. Looking forward to continued engagement with this group!

Thankful to the @ISAC_KUH! These funds have opened up new avenues of research in our lab as we explore how histamine signaling impacts hematopoietic function during aging.

We had a full house today as we welcomed @BDBiosciences to launch our brand new FACSDiscover A8 Cell Analyzer! We’re proud to be one of the first institutions in the Midwest to bring this technology in-house and can’t wait to see the discoveries it helps unlock.

New work from our lab out this week in @StemCellsJournl! We show that small-molecule inhibition of 15-PGDH improves HSC function and boosts engraftment in aged recipients post transplant. Proud of the team @caseccc and excited to keep pushing forward. https://t.co/jMLkahYcZO

Breathing shouldn’t be a battle, but for those with idiopathic pulmonary fibrosis (IPF), it often is. To improve the lives of patients living with this progressive, deadly lung disease, researchers explored a new way to deliver two leading IPF medications – Nintedanib (NTB) and

6/ We’re excited to keep building on this to make existing IPF therapies more effective, more tolerable, and easier to use. Check it out here! https://t.co/WJQvUcaO1q

5/ Using a β-cyclodextrin microparticle platform, we developed a slow-release formulation of nintedanib to reduce dosing frequency. The formulation: ▸ Showed sustained release in vitro ▸ Was well-tolerated in mice ▸ 2 low-dose injections ≈ 14 days of high-dose drug

4/ While effective, nintedanib suffers from poor adherence- due to off-target side effects and a 2x daily dosing schedule.

3/In this study, we developed a microparticle system for sustained delivery of nintedanib, one of only two FDA-approved drugs for idiopathic pulmonary fibrosis.

2/First, huge shoutout to first author Emmanuel Opolot- he will be finishing his PhD in BME this year and is someone I’d 100% recommend to any academic or industry team.

1/Excited to share a new team science publication from our lab @caseccc in collaboration with @HA_vonRecum in @CWRUbme. A quick thread outlining our studies...

Bittersweet saying goodbye to Rahul Chaudhary. From an overly earnest undergrad, to seasoned research technician, to medical school in the fall! Very proud of him, and grateful for his time in our lab. @caseccc

Just found out the study section scheduled to review my grant today was canceled. I spent three months writing it, representing five years of work from my lab. Gutted. @NIH

“The impact of the collective executive orders and directives appears devastating.”

Check out our new review published in @ISEHSociety journal Experimental Hematology, asking the question: to what degree is HSC dysfunction responsible for hematologic aging https://t.co/AeFYRowbvS written by @FeniaFotop @DussiauC @Esther_RCorrea @ELShematology

A little holiday cheer with the current (and future) members of the lab! Very grateful for this team and this energy.